This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Aug 1;74(8):1339-1341.

doi: 10.2337/dbi25-0028.

Glucokinase Activators. A Humbling Lesson in Drug Development

Loranne Agius¹, Mark A Magnuson²

Affiliations

Affiliations

¹ Biosciences Institute, Faculty of Medicine, Newcastle University, Newcastle upon Tyne, U.K.
² Departments of Molecular Physiology and Biophysics, Cell and Developmental Biology, and Medicine, Vanderbilt University, Nashville, TN.

PMID: 40690616
DOI: 10.2337/dbi25-0028

Editorial

Glucokinase Activators. A Humbling Lesson in Drug Development

Loranne Agius et al. Diabetes. 2025.

. 2025 Aug 1;74(8):1339-1341.

doi: 10.2337/dbi25-0028.

Authors

Loranne Agius¹, Mark A Magnuson²

Affiliations

¹ Biosciences Institute, Faculty of Medicine, Newcastle University, Newcastle upon Tyne, U.K.
² Departments of Molecular Physiology and Biophysics, Cell and Developmental Biology, and Medicine, Vanderbilt University, Nashville, TN.

PMID: 40690616
DOI: 10.2337/dbi25-0028

No abstract available

PubMed Disclaimer

Comment on

Functional and Mechanistic Explanation for the Unique Clinical Success of the Glucokinase Activator Dorzagliatin in the Treatment of Type 2 Diabetes.
Roman J, Yuan Y, Xu Y, Zhu Q, Wu S, Zhao F, Zhou X, Meng S, Han D, Sharp K, Chen L, Li C, Doliba NM. Roman J, et al. Diabetes. 2025 Aug 1;74(8):1374-1384. doi: 10.2337/db25-0066. Diabetes. 2025. PMID: 40272935 Free PMC article.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems